We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

68 hedge funds and large institutions have $281M invested in Monte Rosa Therapeutics in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

614% more call options, than puts

Call options by funds: $685K | Put options by funds: $96K

24% more capital invested

Capital invested by funds: $227M → $281M (+$54.2M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.69% less ownership

Funds ownership: 80.24% → 79.55% (-0.69%)

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

4% less funds holding

Funds holding: 71 → 68 (-3)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Holders
68
Holders Change
-3
Holders Change %
-4.23%
% of All Funds
0.98%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
20
Reduced
22
Closed
13
Calls
$685K
Puts
$96K
Net Calls
+$589K
Net Calls Change
-$1.07M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$924K
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$716K
3
Millennium Management
Millennium Management
New York
+$491K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$287K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$284K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.17M
2
CS
Candriam SCA
Luxembourg
-$763K
3
Morgan Stanley
Morgan Stanley
New York
-$636K
4
CM
Caption Management
Oklahoma
-$512K
5
BlackRock
BlackRock
New York
-$385K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$54.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$37.7M -$1.17M -196,437 -4%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$35.9M +$924K +155,880 +3%
BBA
4
Baker Bros. Advisors
New York
$34.7M – – –
ACA
5
Avoro Capital Advisors
New York
$32M – – –
BlackRock
6
BlackRock
New York
$16.3M -$385K -64,971 -3%
Vanguard Group
7
Vanguard Group
Pennsylvania
$11.5M +$281K +47,412 +3%
ACM
8
Aisling Capital Management
New York
$10.4M – – –
AI
9
Alphabet Inc
California
$10.3M – – –
Citadel Advisors
10
Citadel Advisors
Florida
$6.91M -$21K -3,546 -0.4%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$5.19M +$284K +47,862 +7%
State Street
12
State Street
Massachusetts
$4.34M +$248K +41,842 +7%
CC
13
Casdin Capital
New York
$3.6M – – –
Northern Trust
14
Northern Trust
Illinois
$2.05M +$32.7K +5,520 +2%
ECM
15
ExodusPoint Capital Management
New York
$1.87M +$210K +35,474 +15%
Charles Schwab
16
Charles Schwab
California
$1.77M +$29.8K +5,020 +2%
TD Asset Management
17
TD Asset Management
Ontario, Canada
$1.36M – – –
Millennium Management
18
Millennium Management
New York
$1.06M +$491K +82,746 +123%
Renaissance Technologies
19
Renaissance Technologies
New York
$861K +$100K +16,900 +16%
Wellington Management Group
20
Wellington Management Group
Massachusetts
$851K +$716K +120,647 New
Manulife (Manufacturers Life Insurance)
21
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$727K -$8.63K -1,456 -1%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$663K -$38.5K -6,497 -6%
N
23
Nuveen
North Carolina
$628K – – –
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$512K +$287K +48,362 +199%
SP
25
Sarasin & Partners
United Kingdom
$459K – – –
1
2 3 4

GLUE Hedge Fund Activity: Q1 2024 in Review

68 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2024, worth a combined $281M — up 24% from $227M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of GLUE and 10 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 20 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $924K. The largest seller was Fidelity Investments, cutting an estimated $1.17M.

  • 68 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2024, down from 71 in Q4 2023.
  • Funds reported $281M of Monte Rosa Therapeutics stock for Q1 2024, up 24% quarter-over-quarter.
  • 10 funds opened new Monte Rosa Therapeutics positions in Q1 2024 and 13 closed out, a net change of -3 holders.
  • The largest Monte Rosa Therapeutics buyer in Q1 2024 was T. Rowe Price Associates, an estimated $924K added.
  • The largest Monte Rosa Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $1.17M sold.

Based on aggregated 13F filings for Q1 2024.